NMD Pharma A/S, a Danish biotech developing therapies for severe neuromuscular disorders, has landed a €38 million (US$46.9 million) series A financing. Proceeds from the round are expected to back proof-of-concept studies for an oral therapy targeting the orphan neuromuscular disorder myasthenia gravis and, in the critical care setting, an I.V. therapy for the reversal of muscular blockade in connection with surgery. The studies are expected to take three to five years to complete.